Evaluation of iron replacement therapy efficiency using a complex panel of biomarkers

1. Marton I, Agócs S, Babik B. Az anaemiák epidemiológiája. [Epidemiology of anemia]. Orv Hetil. 2020;161(37):1569-73. DOI: 10.1556/650.2020.3191610.1556/650.2020.3191632894736Search in Google Scholar

2. FAO, WHO. World Declaration and Plan of Action for Nutrition. International Conference on Nutrition. Rome, Food and Agriculture Organization of the United Nations, December 1992.Search in Google Scholar

3. McLean E, Cogswell M, Egli I, de Benoist B. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Geneva, Switzerland World Health Organization. 2008.Search in Google Scholar

4. Kassebaum NJ, Jasrasaria R, Naghavi M, Wuklf SK, Johns N, Lozano R et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 1990;123(5):615-24. DOI: 10.1182/blood-2013-06-50832510.1182/blood-2013-06-508325390775024297872Search in Google Scholar

5. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639-48. DOI: 10.1111/bjh.1231110.1111/bjh.1231123573815Search in Google Scholar

6. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Niniraki M, Kouroumalis EA. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol. 2011;24(2):108-14.Search in Google Scholar

7. Tijanić I, Vučić M, Golubovic LM. The significance of soluble transferrin receptors in diagnosing iron deficiency anemia. Rev Romana Med Lab. 2015;23(3):275-83. DOI: 10.1515/rrlm-2015-003010.1515/rrlm-2015-0030Search in Google Scholar

8. Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets. 2019;23(5):407-21. DOI: 10.1080/14728222.2019.159935810.1080/14728222.2019.159935830907175Search in Google Scholar

9. Nakanishi T, Kimura T, Kuragano T. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease. Contrib Nephrol 2019;198:124-34. DOI: 10.1159/00049663610.1159/00049663630991414Search in Google Scholar

10. Miseta A, Nagy J, Nagy T, Poór VS, Fekete Zs, Sipos K. Hepcidin and its potential clinical utility. Cell Biol Int. 2015;39(11):1191-202. DOI: 10.1002/cbin.1050510.1002/cbin.1050526109250Search in Google Scholar

11. Van Den Bossche J, Devreese K, Malfait R, Van de Vyvere M, Wauters A, Neeis H, et al. Reference Intervals for a Complete Blood Count Determined on different Automated Haematology Analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. 2002;40(1):69-73. DOI: 10.1515/CCLM.2002.01410.1515/CCLM.2002.01411916274Search in Google Scholar

12. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI: 10.1056/NEJMra04180910.1056/NEJMra04180915758012Search in Google Scholar

13. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832-43. DOI: 10.1056/NEJMra140103810.1056/NEJMra140103825946282Search in Google Scholar

14. Hempel E V., Bollard ER. The Evidence-Based Evaluation of Iron Deficiency Anemia. Med Clin North Am. 2016;100(5):1065-75. DOI: 10.1016/j. mcna.2016.04.015Search in Google Scholar

15. Retteghy TA. A vértakarékos betegellátás a perioperatív szakban. [Perioperative Patient Blood Management]. Hematológia−Transzfuziológia. 2018;51(4):194-203. DOI: 10.1556/2068.2018.51.4.410.1556/2068.2018.51.4.4Search in Google Scholar

16. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ, Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE. Public Library of Science; 2015;10(2):e0117383. DOI: 10.1371/journal. pone.0117383Search in Google Scholar

17. Kloss-Brandstätter A, Erhart G, Lamina C, Meister B, Haun M, Coassin S, et al. Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation. PLoS One. 2012;7(4):e35015. DOI: 10.1371/journal.pone.003501510.1371/journal.pone.0035015Search in Google Scholar

18. Gasché C, Dejaco C, Waldhoer T, Tillinger W, Rein-isch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease: A randomised, controlled trial. Ann Intern Med. 1997;126(10):782-7. DOI: 10.7326/0003-4819-126-10-199705150-0000610.7326/0003-4819-126-10-199705150-00006Search in Google Scholar

19. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-8. DOI: 10.1002/ajh.2420110.1002/ajh.24201Search in Google Scholar

20. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. The Lancet, 2007;369(9572):1502-4. DOI: 10.1016/S0140-6736(07)60689-810.1016/S0140-6736(07)60689-8Search in Google Scholar

21. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6 a):362-72. DOI: 10.1055/s-0031-129630110.1055/s-0031-129630120648928Search in Google Scholar

22. Mu-oz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia, Expert Opin Drug Saf, 2018; 17(2):149-59. DOI: 10.1080/14740338.2018.140000910.1080/14740338.2018.140000929103332Search in Google Scholar

23. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet. 2008;101(1):67-73. DOI: 10.1016/j.ijgo.2007.10.00910.1016/j.ijgo.2007.10.00918234203Search in Google Scholar

24. Coyne DW, Adkinson FN, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63(1):217-24. DOI: 10.1046/j.1523-1755.2003.00703.x10.1046/j.1523-1755.2003.00703.x12472786Search in Google Scholar

25. Eche IM, Owen KL, Eche IJ, Patel P, Sabe M. Safety and Effectiveness of an Accelerated Intravenous Iron Administration Protocol in Hospitalised Patients With Heart Failure. J Cardiovasc Pharmacol Ther. 2021;26(4):365-70. DOI: 10.1177/107424842198987110.1177/107424842198987133563034Search in Google Scholar

26. Hussain I, Bhoyroo J, Butcher A, Koch TA He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013;2013:169107. DOI: 10.1155/2013/16910710.1155/2013/169107Search in Google Scholar

27. Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirk-by BE, Ingram E, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 2016;3(9):e415-25. DOI: 10.1016/S2352-3026(16)30078-310.1016/S2352-3026(16)30078-3Search in Google Scholar

28. Van Empel VP, Lee J, Williams TJ, Kaye DM. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23(3):287-92. DOI: 10.1016/j.hlc.2013.08.00710.1016/j.hlc.2013.08.007Search in Google Scholar

29. Powers JM, Buchanan GR. Diagnosis and Management of Iron Deficiency Anemia. Hematol Oncol Clin North Am. 2014;28(4):729-45. DOI: 10.1016/j. hoc.2014.04.007Search in Google Scholar

30. Johnson Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011;4(3):177-84. DOI: 10.1177/1756283X1139873610.1177/1756283X11398736Search in Google Scholar

31. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: Etiology and evaluation. Blood Cells Mol Dis. 2011;46(2):159-65. DOI: 10.1016/j. bcmd.2010.11.004Search in Google Scholar

32. Baird-Gunning J, Bromley J. Correcting iron deficiency. Aust Prescr. 2016;39(6):193-9. DOI: 10.18773/aust-prescr.2016.069Search in Google Scholar

33. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis; 2001;37(1 Suppl 1):182-238. DOI: 10.1016/S0272-6386(01)70008-X10.1016/S0272-6386(01)70008-XSearch in Google Scholar

34. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12:CD010590. DOI: 10.1002/14651858. CD010590.pub210.1002/14651858Search in Google Scholar

35. Tilea I, Petra DN, Serban RC, Gabor MR, Tilinca MC, Azamfirei L., et al. Short-term impact of iron deficiency in different subsets of patients with precapillary pulmonary hypertension from an Eastern European pulmonary hypertension referral center, Int J Gen Med, 2021;14:3355-66. DOI: 10.2147/IJGM.S31834310.2147/IJGM.S318343828522934285560Search in Google Scholar

36. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. CONFIRMHF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68. DOI: 10.1093/eurheartj/ehu38510.1093/eurheartj/ehu385435935925176939Search in Google Scholar

37. A. M. Naidech, M. J. Kahn, W. Soong, Green D, Hunt Batjer H, Bleck TP. Packed Red Blood Cell Transfusion Causes Greater Hemoglobin Rise at a Lower Starting Hemoglobin in Patients with Subarachnoid Hemorrhage, Neurocrit Care, 2008;9(2):198-203. DOI: 10.1007/s12028-008-9113-810.1007/s12028-008-9113-818542851Search in Google Scholar

38. Dignass A. Farrag K. Stein J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int J Chronic Dis. 2018;2018:9394060. DOI: 10.1155/2018/939406010.1155/2018/9394060587889029744352Search in Google Scholar